# Mary E Law

List of Publications by Year
in descending order



| 13 | 388 | 1307594 7 | 1125743 13 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 14 | 14 | 14 | 771 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The unfolded protein response as a target for anticancer therapeutics. Critical Reviews in Oncology/Hematology, 2018, 127, 66-79. | 4.4 | 102 |
| 2 | Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics. Molecular Pharmacology, 2015, 88, 846-852. | 2.3 | 79 |
| 3 | Rapamycin Disrupts Cyclin/Cyclin-Dependent Kinase/p21/Proliferating Cell Nuclear Antigen Complexes and Cyclin D1 Reverses Rapamycin Action by Stabilizing These Complexes. Cancer Research, 2006, 66, 1070-1080. | 0.9 | 63 |
| 4 | Loss of sirtuin 1 and mitofusin 2 contributes to enhanced ischemia/reperfusion injury in aged livers. Aging Cell, 2018, 17, e12761. | 6.7 | 60 |
| 5 | CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment. Breast Cancer Research, 2016, 18, 80. | 5.0 | 25 |
| 6 | Identification of a small molecule inhibitor of serine 276 phosphorylation of the p65 subunit of NF-Î¹B using in silico molecular docking. Cancer Letters, 2010, 291, 217-224. | 7.2 | 18 |
| 7 | Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells. Oncotarget, 2017, 8, 28971-28989. | 1.8 | 11 |
| 8 | Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway. Cell Death Discovery, 2019, 5, 153. | 4.7 | 9 |
| 9 | A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers. Oncogene, 2019, 38, 4264-4282. | 5.9 | 8 |
| 10 | Repurposing Tranexamic Acid as an Anticancer Agent. Frontiers in Pharmacology, 2021, 12, 792600. | 3.5 | 4 |
| 11 | Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death. Cancer Letters, 2022, 534, 215604. | 7.2 | 4 |
| 12 | Signaling Mechanisms that Suppress the Cytostatic Actions of Rapamycin. PLoS ONE, 2014, 9, e99927. | 2.5 | 3 |
| 13 | Anticancer Agents Derived from Cyclic Thiosulfonates: Structureâ€Reactivity and Structureâ€Activity Relationships. ChemMedChem, 2022, 17, . | 3.2 | 1 |